Meeting
2015 ASCO Annual Meeting
A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).
Authors
Loren S. Michel
Washington Univ School of Medicine, St. Louis, MO
Loren S. Michel , Jessica C. Ley , Tanya Marya Wildes , Kathryn Trinkaus , Douglas Adkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT02101034
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6043)
DOI
10.1200/jco.2015.33.15_suppl.6043
Abstract #
6043
Poster Bd #
366
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2019 ASCO Annual Meeting
A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).
First Author: Margaret T. Kasner
Poster
2016 ASCO Annual Meeting
A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).
First Author: Michael J. Pishvaian
Poster
2015 ASCO Annual Meeting
A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
First Author: Phillip Lee Palmbos